Shares of Aptinyx Inc (NASDAQ:APTX) have earned a consensus rating of “Buy” from the eight analysts that are covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell recommendation and seven have issued a buy recommendation on the company. The average 1-year target price among analysts that have issued a report on the stock in the last year is $12.75.

APTX has been the topic of a number of analyst reports. ValuEngine upgraded Aptinyx from a “hold” rating to a “buy” rating in a report on Thursday, August 1st. Zacks Investment Research raised Aptinyx from a “hold” rating to a “buy” rating and set a $4.25 price target on the stock in a research note on Tuesday, July 16th. Cowen reissued a “buy” rating on shares of Aptinyx in a research note on Monday, June 10th. Cantor Fitzgerald reissued a “buy” rating on shares of Aptinyx in a research note on Tuesday, April 30th. Finally, JPMorgan Chase & Co. lowered Aptinyx from a “neutral” rating to an “underweight” rating in a research report on Tuesday.

Several institutional investors have recently made changes to their positions in the company. A.R.T. Advisors LLC grew its stake in shares of Aptinyx by 15.9% during the second quarter. A.R.T. Advisors LLC now owns 27,000 shares of the company’s stock valued at $90,000 after acquiring an additional 3,695 shares in the last quarter. Gabelli Funds LLC grew its stake in Aptinyx by 45.9% in the second quarter. Gabelli Funds LLC now owns 15,901 shares of the company’s stock worth $53,000 after purchasing an additional 5,000 shares in the last quarter. Metropolitan Life Insurance Co. NY increased its holdings in shares of Aptinyx by 356.6% in the fourth quarter. Metropolitan Life Insurance Co. NY now owns 7,237 shares of the company’s stock valued at $120,000 after buying an additional 5,652 shares in the last quarter. Bank of New York Mellon Corp grew its position in Aptinyx by 30.6% during the 4th quarter. Bank of New York Mellon Corp now owns 43,887 shares of the company’s stock worth $726,000 after purchasing an additional 10,284 shares in the last quarter. Finally, Bank of America Corp DE grew its position in Aptinyx by 430.0% during the 4th quarter. Bank of America Corp DE now owns 13,213 shares of the company’s stock worth $218,000 after purchasing an additional 10,720 shares in the last quarter. Institutional investors own 58.30% of the company’s stock.

Shares of APTX traded up $0.08 on Friday, reaching $3.30. The stock had a trading volume of 2,030 shares, compared to its average volume of 344,108. The stock has a market cap of $118.47 million, a price-to-earnings ratio of -1.24 and a beta of -0.03. The company’s 50-day moving average is $3.62. Aptinyx has a twelve month low of $2.88 and a twelve month high of $32.25.

Aptinyx (NASDAQ:APTX) last announced its earnings results on Monday, August 12th. The company reported ($0.36) EPS for the quarter, beating analysts’ consensus estimates of ($0.52) by $0.16. The firm had revenue of $0.93 million for the quarter, compared to analysts’ expectations of $0.95 million. Aptinyx had a negative return on equity of 37.53% and a negative net margin of 1,166.40%. As a group, equities research analysts anticipate that Aptinyx will post -2.15 EPS for the current fiscal year.

About Aptinyx

Aptinyx Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. It is developing NYX-2925 that is in Phase II clinical trial for the treatment of painful diabetic peripheral neuropathy, as well as in Phase II exploratory clinical trial for fibromyalgia; and NYX-783, an NMDAr receptor that is in Phase I clinical trial for the treatment of post-traumatic stress disorder.

Recommended Story: Quiet Period Expirations

Analyst Recommendations for Aptinyx (NASDAQ:APTX)

Receive News & Ratings for Aptinyx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptinyx and related companies with MarketBeat.com's FREE daily email newsletter.